Norwegian pharmaceutical company Photocure has reported positive preliminary results from two Phase II studies carried out with Visonac, its second-generation photodynamic therapy treatment for moderate-to-severe acne.
The firm says one study showed that Visonac achieved similar efficacy results when compared to previous PDT approaches for the treatment of acne, but was much better tolerated, while the other study confirmed that the overall Visonac procedure could be simplified. The final results from both trials will allow the company to design its Phase III Visonac program.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze